Abstract: Disclosed are embodiments of synthetic garnet materials for use in radiofrequency applications. In some embodiments, increased amounts of bismuth can be added into specific sites in the crystal structure of the synthetic garnet in order to boost certain properties, such as the dielectric constant and magnetization. Accordingly, embodiments of the disclosed materials can be used in high frequency applications, such as in base station antennas.

Abstract: A highly oriented nanometer MAX phase ceramic and a preparation method for a MAX phase in-situ autogenous oxide nanocomposite ceramic. The raw materials comprise a MAX phase ceramic nano-lamellar powder body or a blank body formed by the nano-lamellar powder body, wherein MAX phase ceramic nano-lamellar particles in the powder body or the blank meet the particle size being between 20-400 nm, and the oxygen content is between 0.0001%-20% by mass; MAX phase grains in the ceramic obtained after the raw materials are sintered are lamellar or spindle-shaped, the lamellar structure having a high degree of orientation. Utilizing special properties of the nano-lamellar MAX powder body, orientation occurs during compression and deformation to obtain a lamellar structure similar to that in a natural pearl shell, and such a structure has a high bearing capacity and resistance to external loads and crack propagation, just like a brick used in a building.

Abstract: Methods of forming composite materials, composite materials, and articles. The composite materials may include electromagnetic shielding materials. The methods may include providing a mixture of ultra-high temperature ceramic particles and a liquid preceramic precursor, curing the mixture to form a solid mixture, forming particles of the solid mixture, and pressing the particles into a mold.

Abstract: A method of fabricating a carbon-carbon composite includes mixing a carbon-based matrix precursor with a carbon nanomaterial additive forming a polymeric matrix impregnated with the carbon nanomaterial additive, heating the impregnated polymeric matrix under an inert atmosphere, with temperatures ranging between 350-1100° C. for carbonization followed by graphitization at a temperature greater than 1800° C. The matrix precursor may be a graphitizing or non-graphitizing material. The additive may present basal or edge site carbon atoms or a combination of both. As a result, a carbon-carbon composite composed of the matrix and additive is formed by templating or bond formation, wherein at least 1-D nano-scale or micro-scale structural changes begins at the interface between the matrix and additive and propagates outward from the interface into the matrix, thus adjusting or altering the nano- or micro-structures in the matrix that would not naturally occur in the absence of the additive.

Abstract: Ceramic honeycomb bodies with a matrix of intersecting walls having an interior portion with a first average bulk porosity, and a skin having a second average bulk porosity, wherein the second average bulk porosity is less than the first average bulk porosity. Methods of manufacturing a ceramic honeycomb bodies include providing a firing cycle for the ceramic honeycomb structure such that at least the skin of the honeycomb structure is subjected to a thermal spike in firing temperature while the interior portion of the matrix is subjected to a lesser spike in firing temperature.

Abstract: A heat treated ceramic article includes a ceramic substrate and a ceramic coating on the ceramic substrate. The ceramic coating is a non-sintered ceramic coating that has a different composition than the ceramic substrate. The heat treated ceramic article further includes a transition layer between the ceramic substrate and the ceramic coating, the transition layer comprising first elements from the ceramic coating that have reacted with second elements from the ceramic substrate, wherein the transition layer has a thickness of about 0.1 microns to about 5 microns.

Abstract: A foliar nutritional composition and method for using same for providing nutrients and/or for treating disease in plants. The foliar nutritional composition comprises a metal salt complexed with amino acids from hydrolyzed yeast extract. The metal salt is selected for high solubility using a salt of a metal selected from the group consisting of copper, nickel, zinc, iron, manganese, and combinations thereof. Preferred metal salt are nitrates, chlorides, and combinations thereof. In the method, an aqueous solution of this composition is sprayed on the plant foliage and absorbed by the plant.

Abstract: The invention relates to a cast explosive composition. There is provided a precure castable explosive composition comprising an explosive material, a polymerisable binder, said cross linking reagent comprising at least two reactive groups each of which is protected by a labile blocking group.

Abstract: A shock tube package system and a method of deploying a shock tube package system is provided. The system includes a coreless bundle of shock tubing. The system further includes an outer covering disposed about the periphery of the bundle of shock tubing. The outer covering being made from a flexible or ela In an embodiment, the outer covering is made from a flexible or elastic material such as a textile.

Abstract: A process for the production of trans-1-chloro-3,3,3-trifluoropropene comprises the steps of: i) providing a reactor comprising a cover, a bottom, sidewalls connecting said bottom and said cover, at least one reagent supply line and at least one line for drawing off the products formed, said reactor further containing a liquid phase A; ii) providing a stream B comprising hydrofluoric acid heated to a temperature T1 of from 100° C. to 170° C. and providing a stream C comprising 1,1,3,3-tetrachloropropene and/or 1,3,3,3-tetrachloropropene; stream B and stream C supplying said reactor via said at least one reagent supply line; iii) reacting, in liquid phase A, stream B with stream C to form a stream D comprising trans-1-chloro-3,3,3-trifluoropropene. Step iii) is carried out at a temperature T2 of between 50° C. and 110° C., and the temperature difference between temperature T1 and temperature T2 is greater than 30° C.

Abstract: The production method according to the present disclosure comprises obtaining a product containing the fluoroethane from a fluoroethylene by a reaction in the presence of catalysts. Each catalyst is formed by supporting a noble metal on a carrier. A reactor for performing the reaction is filled with a catalyst having a noble metal concentration of C1 mass % based on the entire catalyst and a catalyst having a noble metal concentration of C2 mass % based on the entire catalyst to form an upstream portion and a downstream portion, respectively; and C1<C2. The reaction is performed by bringing the fluoroethylene represented by formula (3) and hydrogen gas into contact with the upstream portion and the downstream portion in this order.

Abstract: A process for producing at least one haloolefin by dehydrohalogenating a hydrohaloalkane. The dehydrohalogenation process is performed in the liquid phase or vapor phase in the presence or absence of a catalyst at a temperature sufficient to effect conversion of the hydrohaloalkane to a haloolefin (haloalkene) in an adiabatic reaction zone. In particular, the adiabatic reaction zone comprises at least two serially-connected adiabatic reactors and having a heat exchanger disposed in sequence and in fluid communication between each two reactors in series.

Abstract: Implementations of a method of forming a wax ether composition may include: providing a batch of lipids, drying the batch of lipids, and cooling the batch of lipids. The method may also include dosing, with a catalyst, the batch of lipids at 0.1% to 0.3% by weight of the batch of lipids and dissolving the catalyst in the batch of lipids to form a homogenous solution. The method may include adding at least a molar equivalent of a hydrogen donor to the homogenous solution. The method may include sealing and maintaining the homogenous solution and hydrogen donor under atmospheric pressure under reflux until a chemical reaction between the homogenous solution and the hydrogen donor forms a product comprising an ether.

Abstract: Provided is a production method capable of efficiently producing a reduced coenzyme Q10 Form II crystal. The method for producing a reduced coenzyme Q10 Form II crystal includes: adding a reduced coenzyme Q10 Form II crystal as a seed crystal to a solution with a temperature of 32° C. to 43° C., the solution containing fa) at least one organic solvent selected from the group consisting of an alcohol, a hydrocarbon, an aliphatic acid ester and a nitrogen compound, and (b) reduced coenzyme Q10, to prepare a mixture, and precipitating the reduced coenzyme Q10 from the mixture, in the form of the reduced coenzyme Q10 Form II crystal.

Abstract: Hydroxyacetal or hydroxyketal monomers, processes for their preparation, their use to produce degradable polymers, hydroxy-functional intermediates resulting from degradation, and repurposed polymers made from the hydroxy-functional intermediates are described. The invention avoids the energy-intensive conditions normally used to degrade polyurethanes and generates new hydroxy-functional intermediates that can be repurposed or upcycled. Polyurethanes and melamines, materials once destined for a landfill, can have a second life. Incorporation of a photoacid generator into microcapsule core materials and fabrication of the shell from the hydroxy-functional acetal or ketal monomers promotes facile, inside-out, solid-state degradation of the microcapsule shell triggered by UV light and acid generation in a hydrophobic environment. This enables controlled release of flavors, fragrances, biocides, agricultural actives, or other oil-based beneficial agents from within the microcapsules.

Abstract: The present invention relates to a stable crystal form, i.e. form A, of 2-tert-butyl-4-methoxyphenol, and to a new preparation method for the 2-tert-butyl-4-methoxyphenol; and the use of the 2-tert-butyl-4-methoxyphenol and the stable crystal form thereof, i.e. form A, in preparing antitumor drugs or immunomodulator drugs. The stable crystal form, i.e. form A, as expressed by a powder X-ray diffraction pattern in an angle of 2?, using Cu-K? radiation, has at least 3 absorption peaks selected from the following positions: 6.27±0.10, 6.94±0.10, 12.27±0.10, 13.36±0.10, 14.01±0.10, 14.79±0.10, 15.31±0.10, 17.05±0.10, 18.30±0.10, 19.00±0.10, 20.47±0.10, 20.98±0.10, 22.37±0.10, 23.68±0.10, 24.55±0.10, 25.37±0.10, 30.83±0.10, 33.12±0.10, 40.50±0.10, 42.81±0.10.

Abstract: Provided is an improved process of vitamin K2 derivatives preparation, represented by formula (I) wherein n is an integer from 3 to 13.

Abstract: An aim of the present disclosure is to provide a method for producing a fluoroalkoxide, said method being more useful than conventional methods, and the like. The aim can be achieved by a method for producing a compound represented by the following formula (1): (wherein R1 is a fluoroalkyl group optionally containing an oxygen atom between carbon atoms, or a fluoroalkoxy group optionally containing an oxygen atom between carbon atoms, and each R2 is identical to or different from each other and is a hydrocarbon group), the method comprising the step of reacting a compound represented by the following formula (2): with a compound represented by the following formula (3): ?F?NR2)4??(3).

Abstract: The present disclosure provides a process for making trifluoroacetyl iodide (TFAI) in a liquid phase reaction. Specifically, the present disclosure provides a liquid phase reaction of trifluoroacetyl chloride (TFAC) and hydrogen iodide (HI), with or without a catalyst, to form trifluoroacetyl iodide (TFAI). The reaction may be performed at ambient or elevated temperatures.

Abstract: Provided is a method for manufacturing a terephthalate-based composition, the method comprising: a step (S1) of flowing in a dialkyl terephthalate in which alkyl has 7 to 10 carbon atoms and a primary alcohol with a low boiling point having 4 or 5 carbon atoms into a reactor and performing transesterification of the dialkyl terephthalate and the primary alcohol with a low boiling point and a step (S2) of extracting in a reduced pressure an unreacted material and a by-product from the reactor after finishing the transesterification, wherein the step S1 comprises a pressure-applying step in which the pressure of the reactor is 1.5 to 2.5 bar.

Abstract: Methacrylic acid or alkyl methacrylate are produced starting from acrolein, which is available from glycerol or propane.

Abstract: The present invention is directed to a purification method for purifying a fluorine-containing polymerizable monomer of the formula (1), in which the fluorine-containing polymerizable monomer is purified by distillation in the coexistence of a phenolic compound A such as 6-tert-butyl-2,4-xylenol and a phenolic compound B such as 2,2?-methylene-bis(4-methyl-6-tert-butylphenol). By the combined use of the phenolic compound A and the phenolic compound B, it is possible to significantly suppress polymerization or oligomerization of the fluorine-containing polymerizable monomer even during industrial-production-scale distillation and efficiently purify the fluorine-containing polymerizable monomer by distillation.

Abstract: Disclosed herein are drug release polymer compounds and compositions comprising prostacyclin compounds of Formula (I), and methods of preparing the same.

Abstract: Compounds, compositions, and methods related to bioenergetic metabolism are provided. The compounds and com positions are suited to promote bioenergetic processes including cellular respiration and glycolytic flux and may be used to treat mitochondrial disorders, neurodegenerative diseases (such as Alzheimer's disease (AD), Parkinson's disease, and/or amyotrophic lateral sclerosis), multiple sclerosis, and/or epilepsy.

Abstract: Glucose deprivation is an attractive strategy in cancer research and treatment. Cancer cells upregulate glucose uptake and metabolism for maintaining accelerated growth and proliferation rates. Specifically blocking these processes is likely to provide new insights to the role of glucose transport and metabolism in tumorigenesis, as well as in apoptosis. As solid tumors outgrow the surrounding vasculature, they encounter microenvironments with a limited supply of nutrients leading to a glucose deprived environment in some regions of the tumor. Cancer cells living in the glucose deprived environment undergo changes to prevent glucose deprivation-induced apoptosis. Knowing how cancer cells evade apoptosis induction is also likely to yield valuable information and knowledge of how to overcome the resistance to apoptosis induction in cancer cells.

Abstract: To provide a novel arylamine compound with a low refractive index. The provided arylamine compound includes at least one aromatic group. The aromatic group includes a first benzene ring, a second benzene ring, a third benzene ring, and at least three alkyl groups. The first benzene ring, the second benzene ring, and the third benzene ring are directly bonded in this order. The first benzene ring is bonded to nitrogen of amine. The first benzene ring may further include a substituted or unsubstituted phenyl group. The second benzene ring or the third benzene ring may further include an alkylated phenyl group. Each of first positions and third positions of two or more of the first to third benzene rings is independently bonded to another benzene ring, a benzene ring of the alkylated phenyl group, any of the at least three alkyl groups, or the nitrogen of the amine.

Abstract: Cannabidiol quinol derivatives of Formula (I) and compositions comprising the same for use in the treatment of conditions that benefit from the inhibition of the HIF prolyl hydroxylases (PHDs) activity are described. Said cannabidiol quinol derivatives of Formula (I), and compositions comprising the same, show thus capacity to inhibit PHD activities and, as a result, stabilize the HIF-1? and HIF-2? levels, activate the HIF pathway in different cell types, induce angiogenesis in human endothelial vascular cell, regulate HIF-dependent gene expression in different cell types and induce collagen contraction. Said cannabidiol quinol derivatives of Formula (I) are useful in the treatment of conditions that benefit from the inhibition of the HIF prolyl hydroxylases (PHDs) activity such as stroke, traumatic injuries anemia, myocardial ischaemia-reperfusion injury, acute lung injury, infectious diseases, diabetic and chronic wounds, organ transplantation, acute kidney injury or arterial diseases.

Abstract: The invention provides for a synthesised ester intermediate of formula 1. Formula 1 Wherein and wherein R may be a saturated or unsaturated fatty acid (C12-C20).

Abstract: The invention provides polymorphs of a compound of Formula (X): The invention also provided pharmaceutical compositions containing polymorphs of the compound and methods treating conditions in a subject by providing polymorphs of the compound.

Abstract: This application relates to solabegron zwitterion useful for the treatment of lower urinary tract symptoms such as, for example, overactive bladder and prostate disorders. Additionally, this application relates to pharmaceutical compositions and methods of treatment utilizing the solabegron zwitterion for treating lower urinary tract symptoms. This application also relates to methods of preparing solabegron hydrochloride from the solabegron zwitterion.

Abstract: The invention provides for a method for screening compounds that bind to and modulate a histone acetyltransferase protein. The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein as well as cancer by administering a HAT-activating compound to a subject.

Abstract: The present invention relates to dipeptidyl ketoamide m-methoxyphenyl derivatives and their use in the treatment of diseases and conditions associated with elevated calpain activity, such as heart injury caused by infarction, ischemia with or without reperfusion, neurodegenerative disorders, malaria, diabetic nephropathy, neurotoxicity induced by HIV virus, cancer, and fibrotic diseases.

Abstract: This invention relates to compounds of formula 1, 2 or 3 a pharmaceutically acceptable salt, or solvate thereof, wherein X1, Y, R1, R2, R3, R4, and R5 are as defined herein. The compounds are antimicrobial agents that may be used to treat various bacterial and protozoal infections and disorders related to such infections. The invention also relates to pharmaceutical compositions containing the compounds and to methods of treating bacterial and protozoal infections by administering the compounds of formula 1, 2 or 3.

Abstract: The present disclosure encompasses crystalline forms of N1-(1-cyanocyclopropyl)-N2-((1S)-1-{4?-[(1R-2,2-difluoro-1-hydroxyethyl]biphenyl-4-yl}-2,2,2-trifluoroethyl)-4-fluoro-L-leucinamide and processes for the preparation thereof.

Abstract: The present disclosure provides a composition for treating urea particles under ambient atmospheric conditions, a method for treating urea particles with the composition and to a fertiliser treated with the composition. The composition functions to reduce moisture induced agglomeration of treated urea particles compared to moisture induced agglomeration of untreated urea particles. The composition includes a solvent and a mixture of a first and a second aliphatic compound, each compound respectively comprising a selected C8-C14 saturated straight chain hydrocarbon a selected C15-C19 saturated straight chain hydrocarbon.

Abstract: Compounds that inhibit HIF-2?, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2?.

Abstract: The present invention relates to a polythiol composition that includes (a) a polythiol compound (A) having at least two thiol groups; and (b) a nitrogen-containing compound (B) represented by the following Formula (I), In Formula (I), —S—R is a residue of the polythiol compound (A). A peak area of the nitrogen-containing compound (B) is equal to or less than 3.0, with respect to a peak area of 100 of the polythiol compound (A). Each peak area for compounds (A) and (B) is determined by high performance liquid chromatography analysis. The present invention also relates to a polymerizable composition that includes the polythiol composition, and polymerizates thereof.

Abstract: Described is a salt of Formula IIb:

Abstract: Disclosed is a novel diamine having a structure of comprising an intramolecular imide group, and further comprising aromatic cyclic groups linked by an ester group to both sides of the imide group. When the novel diamine is used as a polymerizable component for preparing a polyimide, a polyimide film having remarkably improved mechanical and thermal properties while maintaining optical properties can be provided.

Abstract: The present invention relates to a novel halo-(3-(phenylsulfonyl)prop-1-enyl)pyridine derivative or a pharmaceutically acceptable salt thereof; a preparation method thereof; and an Nrf2 activator and a pharmaceutical composition for preventing or treating diseases induced by a decrease in Nrf2 activity, both of which comprise the same as an active ingredient.

Abstract: Provided herein are compounds useful in treating exposure to an organophosphorus compound, such as a nerve agent, pesticide, or, generally, an acetylcholinesterase inhibitor, such as sarin. Compositions, e.g. pharmaceutical compositions or dosage forms, comprising the compounds also are provided herein. Methods of treating a patient exposed to a nerve agent, pesticide, or, generally, an acetylcholinesterase inhibitor, e.g., an organophosphorus compound, such as sarin, also are provided.

Abstract: The present disclosure relates to solid state forms of Omecamtiv mecarbil and Omecamtiv mecarbil diHCl, processes for preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.

Abstract: The present invention provides a novel 1:1 co-crystal of (rac)-tramadol hydrobromide-celecoxib and processes for the preparation of the same by reacting (rac)-tramadol with hydrobromic acid and celecoxib. It also provides crystalline form of (rac)-tramadol hydrobromide.

Abstract: Disclosed are compounds of Formula 1, including all geometric and stereoisomers, tautomers, N oxides, and salts thereof, wherein R1, R2, R3, R4, R5, R6, m and n are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention.

Abstract: A method of preparing a 2,6 disubstituted anilines includes, reacting a 2-amino isophthalic acid diester with sufficient Grignard reagent R2CH2MgX to form the corresponding diol product, dehydrating the diol product to the corresponding dialkene; and hydrogenating the diol product to form the corresponding aniline. The 2,6 disubstituted anilines can be used to produce N-Heterocyclic Carbenes (NHCs). The NHCs can find application in various fields such as organic synthesis, catalysis and macromolecular chemistry. Palladium catalysts containing the NHCs are also described.

Abstract: The invention relates to substituted phenylpyrimidines of general formula (I), to their agrochemically acceptable salts (I), and to the use thereof in the field of plant protection.

Abstract: Novel compounds are described which decrease the intracellular levels of leucine and methionine. Treatment with these amino acid depletion agents affects many metabolic and life processes which rely upon methionine, leucine and their derivatives. Methionine depletion not only inhibits protein synthesis, but also polyamine biosynthesis and significantly reduces intracellular pools of the native polyamines, spermidine and spermine. Since methionine restriction has been shown to mimic caloric restriction in life extension studies across multiple species, these compounds are also expected to extend lifespan by limiting methionine supply.

Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof. Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an 1DO-associated disease or disorder.

Abstract: The present invention relates to tetrazole containing compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease syndrome, condition, or symptoms, in particular related to chronic pain and inflammation, as a sole agent or in combination with other active ingredients.

Abstract: Provided herein are compounds that can exhibit activity as biofilm modulating agents (e.g., activity as biofilm inhibitors and/or activity as biofilm dispersal agents). The compounds can exhibit potent activity against Gram positive biofilms. The compounds can also exhibit activity against Gram negative biofilms. In some cases, the compounds can exhibit both biofilm modulation properties and antimicrobial activity. Compositions comprising these compounds, as well as methods of using thereof, are also described. For example, the compounds described herein can be used in human and animal health (e.g., for the treatment of infection), agriculture, marine coatings, and other coating applications related to prevention of biofilm (e.g., dental, medical, etc.).